Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase II Study

NCT06556862 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT06556862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06556862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase II Study
Lead sponsor
Beijing 302 Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
December 31, 2028
Enrollment
155 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hr+/her2- advanced breast cancer